Zentalis Pharmaceuticals (ZNTL) Earnings Date, Estimates & Call Transcripts $3.47 -0.48 (-12.15%) (As of 11/15/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Zentalis Pharmaceuticals Latest Earnings SummaryUpcoming Earnings DateFeb. 25EstimatedActual EPS (Nov. 12) -$0.56 Beat By $0.36 Consensus EPS (Nov. 12) -$0.92 Zentalis Pharmaceuticals released Q3 2024 earnings on November 12, 2024, reporting an EPS of -$0.56, which topped the consensus estimate of -$0.92 by $0.36. With a trailing EPS of -$2.49, Zentalis Pharmaceuticals' earnings are expected to decrease next year, from ($2.76) to ($3.34) per share. ZNTL Upcoming EarningsZentalis Pharmaceuticals' next earnings date is estimated for Tuesday, February 25, 2025, based off prior year's reporting schedules. Get Zentalis Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zentalis Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataZNTL Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ZNTL Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] Zentalis Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243-$0.94-$0.41-$0.73Q2 20243-$0.93-$0.47-$0.75Q3 20243-$0.96-$0.86-$0.93Q4 20243-$1.01-$0.66-$0.89FY 202412-$3.84-$2.40-$3.30Q1 20251-$0.69-$0.69-$0.69Q2 20251-$0.70-$0.70-$0.70Q3 20252-$0.67-$0.56-$0.62Q4 20252-$0.68-$0.57-$0.63FY 20256($2.74)($2.52)($2.63) Zentalis Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/25/2025(Estimated)------- 11/12/2024--$0.92-$0.56+$0.36-$0.56--8/9/2024Q2 2024-$0.84-$1.24 -$0.40-$1.24-- 5/7/2024Q1 2024-$0.77$0.14+$0.91$0.14$35.00M$40.56M 2/27/2024Q4 2023-$0.92-$0.83+$0.09-$0.83-- 11/6/2023Q3 2023-$0.92-$0.79+$0.13-$0.79-- 8/9/2023Q2 2023-$1.03-$1.85 -$0.82-$1.85-- Get the Latest News and Ratings for ZNTL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/10/2023Q1 2023-$0.96-$1.07 -$0.11-$1.07-- 3/1/2023Q4 2022-$1.09-$0.92+$0.17-$0.92-- Zentalis Pharmaceuticals Earnings - Frequently Asked Questions When is Zentalis Pharmaceuticals's earnings date? Zentalis Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates. Learn more on ZNTL's earnings history. Did Zentalis Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported ($0.56) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.92) by $0.36. Learn more on analysts' earnings estimate vs. ZNTL's actual earnings. How much profit does Zentalis Pharmaceuticals generate each year? Zentalis Pharmaceuticals (NASDAQ:ZNTL) has a recorded net income of -$292.19 million. ZNTL has generated -$2.49 earnings per share over the last four quarters. What is Zentalis Pharmaceuticals's EPS forecast for next year? Zentalis Pharmaceuticals's earnings are expected to decrease from ($2.81) per share to ($3.37) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Cryoport Earnings Prelude Therapeutics Earnings Ironwood Pharmaceuticals Earnings Phibro Animal Health Earnings Immatics Earnings Collegium Pharmaceutical Earnings CARGO Therapeutics Earnings Prothena Earnings Cullinan Therapeutics Earnings 89bio Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run 2024's Must-Watch Stocks! (Ad)Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] This page (NASDAQ:ZNTL) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
